CA2206394A1 - Radiation therapy method and device - Google Patents
Radiation therapy method and deviceInfo
- Publication number
- CA2206394A1 CA2206394A1 CA002206394A CA2206394A CA2206394A1 CA 2206394 A1 CA2206394 A1 CA 2206394A1 CA 002206394 A CA002206394 A CA 002206394A CA 2206394 A CA2206394 A CA 2206394A CA 2206394 A1 CA2206394 A1 CA 2206394A1
- Authority
- CA
- Canada
- Prior art keywords
- medical device
- radioisotope
- stent
- radiation
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0095—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof radioactive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
- A61N2005/1019—Sources therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
Abstract
An implantable medical device is used to deliver a dosage of radiation to a localized site within a patient. The device is coated with a chelator selected for its bonding affinity with a specific radioisotope. A base layer and optionally a spacer layer first is applied to the device to provide a proper foundation for the chelator. Just prior to implantation, the device is immersed in a solution of the radioisotope which enables a preselected amount of such radioisotope, to be adsorbed.
Description
CA 02206394 1997-0~-27 RADIATION THERAPY METHOD AND DEVICE
BACKGROUND OF THE INVENTION
The present invention generally relates to the use of radiation therapy to treat a condition such as restenosis and, more particularly, pertains to the use of an implantable device to deliver a dose of radiation.
A variety of conditions have been found to be amenable to treatment by the local irradiation of tissue. In order to appropriately limit the amount of tissue that is irradiated, it sometimes is necessary to implant a small source of radiation and, in order to expose the tissue to a sufficient dosage of radiation, it has been found advantageous to implant such device for an extended period of time.
Percutaneoustransluminal coronaryangioplasty (PTCA) is an established treatment for coronary artery disease. The procedure involves inserting a balloon catheter through the vasculature to a position where atherosclerotic plaque has collected on the vessel wall. The plaque is compressed against the vessel wall by inflating the balloon located at the distal end of the catheter in order to increase the diameter of the vessel and thereby reduce the restriction to blood flow. After sufficient expansion has been achieved, the balloon is deflated and removed, and the area of disruption begins to heal.
While this procedure is very widely used, one problem associated with PTCA is a condition known as restenosis.
Restenosis is the development of further blockage in the intravascular structure, following an otherwise successful angioplasty procedure. Restenosis is believed to be an exaggerated form of the normal healing process of the stretched tissue. Restenosis is thought to be caused by fibrointimal proliferation of the stretched wall in which the injured cells lining the vascular structure multiply and form fibrous tissue.
Such growth at the vascular wall is an almost malignant phenomenon in which normal cells multiply at a high rate, thereby creating a new obstruction to flow through the vascular structure. It occurs in the range of approximately 15-50 percent of the PTCA cases and typically presents within the CA 02206394 1997-0~-27 first six months following PTCA. Stents have been implanted in expanded vessels in an effort to maintain patency but do not appear to have much of an effect on the restenosis rate. In the event a stent has been implanted, the growth tends to occur around its ends and through any openings in its walls.
Localized irradiation of the vessel from within the vessel has been found to be effective in reducing the incidence of restenosis. To date, such radiation has been delivered via a number of different vehicles, including by guide wire, balloon, temporarily implantable wire or permanently-implantable stent. The delivery device either is partially or wholly formed of radioactive material or alternatively, is coated with a radioactive substance. Material giving off high levels of radiation may be introduced briefly into the body and then removed. Alternatively, material giving off a relatively lower level of radiation and with an appropriately short half-life may be introduced temporarily or, in some instances, left in place.
A number of shortcomings or disadvantages are associated with the prior art devices and techniques. With respect to temporarily implanted devices, implantation time is limited and therefore the radiation dose necessarily must be very high. At such high dosage rates, local radiation burns may be caused on one side of the vessel while the opposite side may receive a suboptimum dose. Moreover, due to the tendency of restenosis to occur throughout a six month period, repeated irradiation procedures would be necessary in order to adequately address the vagaries of onset.
In the case of permanently implanted devices, a compromise be made between the shelf life of the device and its in-vivo efficacious lifetime. If materials with short half-lives are used, in order to reduce the long term exposure of the patient to radiation, then the shelf life of the device necessarily must be short and therefore is undesirable. If, on the other hand, an isotope is used which will permit a substantial shelf life, i.e., an isotope having a long half-life, then the exposure of the patient to radiation will be CA 02206394 1997-0~-27 long term and may be excessive. Moreover, in view of the fact that the development of restenosis typically occurs within the first six months, it has been recognized that it is desirable to limit irradiation to such a time frame. Of course, attempting to substantially restrict the release of radiation from a permanently implantable device to such a limited period of time imposes further constraints on the shelf life of the devlce .
Another disadvantage inherent in the heretofore known delivery devices is related to the need to adequately protect from exposure to unreasonable radiation dosages all who handle the device, including the manufacturing, stocking, and shipping personnel, catheter laboratory personnel, and physicians.
This requires the use of large and cumbersome containers that further complicate handling and disposal concerns. Some of the radioisotopes being considered in the industry require ion implantation into the device or transmutation of the metal in the device. The complexity of such processes greatly increases the cost of the devices.
A new approach is necessary that would overcome the shortcomings of the prior art. It would be desirable to provide a system by which a very predictable dosage of radiation can be delivered via a permanently implantable device. Moreover, it would be most desirable for such device to be producible at minimal cost, to have a substantial shelf life and present a minimal risk of exposure to radiation.
SUMMARY OF THE INVENTION
The present invention overcomes the shortcomings of the techniques and devices heretofore employed to deliver a dose of radiation to a vascular site. A method is provided for precisely controlling the dosage that is delivered to the patient, while concerns relating to shelf-life of the device are obviated. Moreover, the hazards with respect to the handling of radioactive devices are substantially mitigated.
Additionally, the present invention provides a method for CA 02206394 1997-0~-27 quickly and easily rendering an implantable device radioactive.
More particularly, an implantable device is prepared so as to readily adsorb a preselected amount of radioactive material and to form a sufficiently strong bond therewith so as to substantially minimize any subsequent loss thereof upon contact with bodily fluids. The present invention further provides a stent or other implantable device which facilitates the practice of such method.
These advantages generally are achieved by maintaining separate the implantable hardware and the radioactive material until just prior to implantation. By loading a precisely known quantity of material with a known half-life onto the device and immediately proceeding with the implantation procedure, a very precise dose of radiation can be delivered to the patient over a desired period of time.
Particular embodiments of present invention provide a stent that facilitates the adsorption of a predictable amount of radioactive material thereon in the surgery room. More particularly, a stent is provided that is coated with a chelating agent. A base material and, optionally, a spacer material first is coated onto the device, after which the chelator is applied. This approach obviates any shelf life concerns related to the stent itself and obviates the need for special handling of the stent prior to loading. The base material is selected to both form a strong bond with the surface of the stent as well as with the spacer or chelator applied thereover. The spacer is selected to form a strong bond with the underlying base layer as well as with the chelator and serves to impart a degree of mobility to the chelator or to increase the number of active sites. Finally, the chelator is selected to form a strong bond with the base layer or spacer layer therebelow and of course ultimately adsorb the radioactive isotope. Such combinations of coatings are fairly tenacious, are substantially unaffected by the disinfection processes the stent is normally subjected to and have no effect on the shelf life of the stent.
CA 02206394 1997-0~-27 Just prior to implantation, the chelator-coated device is immersed in a solution containing the appropriate radioactive material to adsorb the radioisotope. The chelator-isotope combination can be chosen such that the loading is quantitative with virtually no subsequent release of the radioactive material from the implanted stent. Knowing the activity of the material along with the half-life of the radioisotope renders precisely calculable the total dosage of radiation that will be delivered. Precautions relating to the radiation must only be taken when handling the vial containing the radioactive material and when handling the stent during and after the loading step.
These and other features and advantages of the present invention will become apparent from the following detailed description of preferred embodiments which, taken in conjunction with the accompanying drawing, illustrate by way of example the principles of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 is a perspective view of a typical stent having an open lattice structure and embodying features of the present invention.
FIG. 2 is a cross-section of one wire strut of the stent of FIG. 1 depicting the various layers attached to the stent.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Particular embodiments of the present invention provide a system for delivering a precise dose of radiation to a vascular site via an implantable device. The device for example may be used to prevent restenosis in a blood vessel that had been subjected to an angioplastic procedure.
The device of the present invention preferably takes the form of a permanently implantable stent 10. The stent 10 CA 02206394 1997-0~-27 initially is provided in a collapsed state and positioned about an inflatable balloon on the distal end of a catheter. Upon maneuvering the balloon into place within the target blood vessel, the balloon is inflated, which causes the stent to radially expand. Any of various mechanisms well known in the art may be incorporated in the stent in order to lock the stent into its expanded state. Subsequent deflation of the balloon and extraction of the catheter leaves the expanded stent in place to maintain the patency of the blood vessel. Further details of expandable stents and a balloon catheter delivery system are found in U.S. Patent No. 5,569,295, which issued October 29, 1996 to Advanced Cardiovascular Systems, Inc. on an application filed May 3, 1995.
A stent 10 is prepared in accordance with the present invention to deliver a preselected dose of radiation. FIGS. 1 and 2 depict the stent 10 embodying features of the present invention. The exterior surface 12 of the stent 10 first is selectively coated with a base layer 14 that serves as a primer or foundation. The base material is selected for its ability to adhere or bond to the surface of the stent while providing a surface to which the next layer readily bonds. An intermediate spacer layer 16 optionally is bonded to the base layer for the purpose of providing sufficient mobility to the chelating functionality that subsequently is applied thereto and/or to increase the number of active sites available to the chelating moiety thereby serving as a chemical amplifier. The chelator 18 is attached covalently to either the spacer material 16 or directly to the base layer 14. The chelator is selected to form a strong bond with the underlying material and to have a strong affinity for the particular radioisotope to be used. The top layer is applled just prior to use and comprises the radioisotope that is adsorbed by the chelator. The radioisotope is selected based on the type of radiation it emits and its half-life.
The stent may be constructed of metal or a polymer.
Stainless steel is the preferred material of construction.
CA 02206394 1997-0~-27 The base layer may comprise gold or any organic coating that contains a nucleophile, or potential nucleophile.
These sites potentially could be aliphatic or benzylic carbons alpha to an ester, ketone or nitrile (i.e., aliphatic or benzylic carbons in the alpha position of an ester, ketone or nitrile). Alternatively, they could be alcohols, amines, ureas or thiols. Possible base layers include polyurethane, poly (ethylene-vinyl alcohols), poly (vinyl alcohols), most hydrogels and polyarcylates.
The spacer layer preferably is attached to the base layer by nucleophilic substitution due to the degree of control afforded by such reaction. Alternatively, radical grafting processes may be employed. Possible spacer materials include ~, ~- mercaptoalkylamines, diisocyanates, diacid chlorides, dialkylamines, ~, ~- hydroxyalkylamines, dihydroxyalkanes (PE0) and dimercaptoalkanes.
The chelator is selected to form a covalent bond with the underlying layer, i.e., either the spacer or the base, and for a very high binding affinity for the radioisotope.
Possible chelator functionalities include acetates (monocarboxylic acids), acetylacetone, benzoylacetone, citric acid, 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, ethylenediamine-N,N,N',N'-tetraacetic acid, and pyridine-2,6-dicarboxylic acid.
The radioisotope is selected based on the type of emission, its half-life and the strength of its bond to the chelator, which must be sufficient so as not to be displaced by ions present in the blood. The preferred isotope is a beta emitter, because gamma radiation penetrates too deeply into tissue and the energy of alpha particles is insufficient. The half-life of the radioisotope should be between 24 hours and 2 months, preferably between 2-18 days. The shorter the half-life, the more problematic becomes the shipping and storage of the radioactive material, while the longer the half-life, the more excessive becomes the delivered the dosage in view of the biological process currently understood to be involved in the processes of restenosis.
CA 02206394 1997-0~-27 The most preferred combination of materials is a stainless steel stent, a gold base layer, alpha, omega mercaptoalkylamine as a spacer, Nl-(2-hydroxethyl)-ethylenedramine - N,N,Nl - triacetic acid as a chelator and Irl92 as the radioisotope.
In the practice of the invention, the stent first is prepared by applying the base layer, then optionally the spacer layer and finally the chelator. The coated stent subsequently is sterilized and processed along with the stent and associated devices. The subsequent shelf life and handling constraints substantially are dictated by the base stent and catheter rather than by the coating.
The radioisotope, suspended in a solution contained in a vial, is handled separately according to the general methods with which hospitals are acquainted. Just prior to implantation, the stent is immersed in the vial in order to allow the chelator to adsorb the radioisotope. The loaded stent subsequently is maneuvered into position within the patient and expanded to be permanently left in place. The radiation emitted by stent gradually diminishes as a function of its half-life but is sufficient during the critical six month time frame to preclude or at least minimize the chance of restenosis. Radiation subsequently continues to subside to insignificant levels obviating the need to remove the device.
While a particular form of the invention has been illustrated and described, it also will be apparent to those skilled in the art that various modifications can be made without departing from the scope of the invention. More particularly, any type of implantable device may be prepared in accordance with the invention and the method may b-e practiced to treat any type of condition that has been found to respond to the localized irradiation of tissue. Accordingly, it is not intended that the invention be limited except by the appended claims.
BACKGROUND OF THE INVENTION
The present invention generally relates to the use of radiation therapy to treat a condition such as restenosis and, more particularly, pertains to the use of an implantable device to deliver a dose of radiation.
A variety of conditions have been found to be amenable to treatment by the local irradiation of tissue. In order to appropriately limit the amount of tissue that is irradiated, it sometimes is necessary to implant a small source of radiation and, in order to expose the tissue to a sufficient dosage of radiation, it has been found advantageous to implant such device for an extended period of time.
Percutaneoustransluminal coronaryangioplasty (PTCA) is an established treatment for coronary artery disease. The procedure involves inserting a balloon catheter through the vasculature to a position where atherosclerotic plaque has collected on the vessel wall. The plaque is compressed against the vessel wall by inflating the balloon located at the distal end of the catheter in order to increase the diameter of the vessel and thereby reduce the restriction to blood flow. After sufficient expansion has been achieved, the balloon is deflated and removed, and the area of disruption begins to heal.
While this procedure is very widely used, one problem associated with PTCA is a condition known as restenosis.
Restenosis is the development of further blockage in the intravascular structure, following an otherwise successful angioplasty procedure. Restenosis is believed to be an exaggerated form of the normal healing process of the stretched tissue. Restenosis is thought to be caused by fibrointimal proliferation of the stretched wall in which the injured cells lining the vascular structure multiply and form fibrous tissue.
Such growth at the vascular wall is an almost malignant phenomenon in which normal cells multiply at a high rate, thereby creating a new obstruction to flow through the vascular structure. It occurs in the range of approximately 15-50 percent of the PTCA cases and typically presents within the CA 02206394 1997-0~-27 first six months following PTCA. Stents have been implanted in expanded vessels in an effort to maintain patency but do not appear to have much of an effect on the restenosis rate. In the event a stent has been implanted, the growth tends to occur around its ends and through any openings in its walls.
Localized irradiation of the vessel from within the vessel has been found to be effective in reducing the incidence of restenosis. To date, such radiation has been delivered via a number of different vehicles, including by guide wire, balloon, temporarily implantable wire or permanently-implantable stent. The delivery device either is partially or wholly formed of radioactive material or alternatively, is coated with a radioactive substance. Material giving off high levels of radiation may be introduced briefly into the body and then removed. Alternatively, material giving off a relatively lower level of radiation and with an appropriately short half-life may be introduced temporarily or, in some instances, left in place.
A number of shortcomings or disadvantages are associated with the prior art devices and techniques. With respect to temporarily implanted devices, implantation time is limited and therefore the radiation dose necessarily must be very high. At such high dosage rates, local radiation burns may be caused on one side of the vessel while the opposite side may receive a suboptimum dose. Moreover, due to the tendency of restenosis to occur throughout a six month period, repeated irradiation procedures would be necessary in order to adequately address the vagaries of onset.
In the case of permanently implanted devices, a compromise be made between the shelf life of the device and its in-vivo efficacious lifetime. If materials with short half-lives are used, in order to reduce the long term exposure of the patient to radiation, then the shelf life of the device necessarily must be short and therefore is undesirable. If, on the other hand, an isotope is used which will permit a substantial shelf life, i.e., an isotope having a long half-life, then the exposure of the patient to radiation will be CA 02206394 1997-0~-27 long term and may be excessive. Moreover, in view of the fact that the development of restenosis typically occurs within the first six months, it has been recognized that it is desirable to limit irradiation to such a time frame. Of course, attempting to substantially restrict the release of radiation from a permanently implantable device to such a limited period of time imposes further constraints on the shelf life of the devlce .
Another disadvantage inherent in the heretofore known delivery devices is related to the need to adequately protect from exposure to unreasonable radiation dosages all who handle the device, including the manufacturing, stocking, and shipping personnel, catheter laboratory personnel, and physicians.
This requires the use of large and cumbersome containers that further complicate handling and disposal concerns. Some of the radioisotopes being considered in the industry require ion implantation into the device or transmutation of the metal in the device. The complexity of such processes greatly increases the cost of the devices.
A new approach is necessary that would overcome the shortcomings of the prior art. It would be desirable to provide a system by which a very predictable dosage of radiation can be delivered via a permanently implantable device. Moreover, it would be most desirable for such device to be producible at minimal cost, to have a substantial shelf life and present a minimal risk of exposure to radiation.
SUMMARY OF THE INVENTION
The present invention overcomes the shortcomings of the techniques and devices heretofore employed to deliver a dose of radiation to a vascular site. A method is provided for precisely controlling the dosage that is delivered to the patient, while concerns relating to shelf-life of the device are obviated. Moreover, the hazards with respect to the handling of radioactive devices are substantially mitigated.
Additionally, the present invention provides a method for CA 02206394 1997-0~-27 quickly and easily rendering an implantable device radioactive.
More particularly, an implantable device is prepared so as to readily adsorb a preselected amount of radioactive material and to form a sufficiently strong bond therewith so as to substantially minimize any subsequent loss thereof upon contact with bodily fluids. The present invention further provides a stent or other implantable device which facilitates the practice of such method.
These advantages generally are achieved by maintaining separate the implantable hardware and the radioactive material until just prior to implantation. By loading a precisely known quantity of material with a known half-life onto the device and immediately proceeding with the implantation procedure, a very precise dose of radiation can be delivered to the patient over a desired period of time.
Particular embodiments of present invention provide a stent that facilitates the adsorption of a predictable amount of radioactive material thereon in the surgery room. More particularly, a stent is provided that is coated with a chelating agent. A base material and, optionally, a spacer material first is coated onto the device, after which the chelator is applied. This approach obviates any shelf life concerns related to the stent itself and obviates the need for special handling of the stent prior to loading. The base material is selected to both form a strong bond with the surface of the stent as well as with the spacer or chelator applied thereover. The spacer is selected to form a strong bond with the underlying base layer as well as with the chelator and serves to impart a degree of mobility to the chelator or to increase the number of active sites. Finally, the chelator is selected to form a strong bond with the base layer or spacer layer therebelow and of course ultimately adsorb the radioactive isotope. Such combinations of coatings are fairly tenacious, are substantially unaffected by the disinfection processes the stent is normally subjected to and have no effect on the shelf life of the stent.
CA 02206394 1997-0~-27 Just prior to implantation, the chelator-coated device is immersed in a solution containing the appropriate radioactive material to adsorb the radioisotope. The chelator-isotope combination can be chosen such that the loading is quantitative with virtually no subsequent release of the radioactive material from the implanted stent. Knowing the activity of the material along with the half-life of the radioisotope renders precisely calculable the total dosage of radiation that will be delivered. Precautions relating to the radiation must only be taken when handling the vial containing the radioactive material and when handling the stent during and after the loading step.
These and other features and advantages of the present invention will become apparent from the following detailed description of preferred embodiments which, taken in conjunction with the accompanying drawing, illustrate by way of example the principles of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGURE 1 is a perspective view of a typical stent having an open lattice structure and embodying features of the present invention.
FIG. 2 is a cross-section of one wire strut of the stent of FIG. 1 depicting the various layers attached to the stent.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
Particular embodiments of the present invention provide a system for delivering a precise dose of radiation to a vascular site via an implantable device. The device for example may be used to prevent restenosis in a blood vessel that had been subjected to an angioplastic procedure.
The device of the present invention preferably takes the form of a permanently implantable stent 10. The stent 10 CA 02206394 1997-0~-27 initially is provided in a collapsed state and positioned about an inflatable balloon on the distal end of a catheter. Upon maneuvering the balloon into place within the target blood vessel, the balloon is inflated, which causes the stent to radially expand. Any of various mechanisms well known in the art may be incorporated in the stent in order to lock the stent into its expanded state. Subsequent deflation of the balloon and extraction of the catheter leaves the expanded stent in place to maintain the patency of the blood vessel. Further details of expandable stents and a balloon catheter delivery system are found in U.S. Patent No. 5,569,295, which issued October 29, 1996 to Advanced Cardiovascular Systems, Inc. on an application filed May 3, 1995.
A stent 10 is prepared in accordance with the present invention to deliver a preselected dose of radiation. FIGS. 1 and 2 depict the stent 10 embodying features of the present invention. The exterior surface 12 of the stent 10 first is selectively coated with a base layer 14 that serves as a primer or foundation. The base material is selected for its ability to adhere or bond to the surface of the stent while providing a surface to which the next layer readily bonds. An intermediate spacer layer 16 optionally is bonded to the base layer for the purpose of providing sufficient mobility to the chelating functionality that subsequently is applied thereto and/or to increase the number of active sites available to the chelating moiety thereby serving as a chemical amplifier. The chelator 18 is attached covalently to either the spacer material 16 or directly to the base layer 14. The chelator is selected to form a strong bond with the underlying material and to have a strong affinity for the particular radioisotope to be used. The top layer is applled just prior to use and comprises the radioisotope that is adsorbed by the chelator. The radioisotope is selected based on the type of radiation it emits and its half-life.
The stent may be constructed of metal or a polymer.
Stainless steel is the preferred material of construction.
CA 02206394 1997-0~-27 The base layer may comprise gold or any organic coating that contains a nucleophile, or potential nucleophile.
These sites potentially could be aliphatic or benzylic carbons alpha to an ester, ketone or nitrile (i.e., aliphatic or benzylic carbons in the alpha position of an ester, ketone or nitrile). Alternatively, they could be alcohols, amines, ureas or thiols. Possible base layers include polyurethane, poly (ethylene-vinyl alcohols), poly (vinyl alcohols), most hydrogels and polyarcylates.
The spacer layer preferably is attached to the base layer by nucleophilic substitution due to the degree of control afforded by such reaction. Alternatively, radical grafting processes may be employed. Possible spacer materials include ~, ~- mercaptoalkylamines, diisocyanates, diacid chlorides, dialkylamines, ~, ~- hydroxyalkylamines, dihydroxyalkanes (PE0) and dimercaptoalkanes.
The chelator is selected to form a covalent bond with the underlying layer, i.e., either the spacer or the base, and for a very high binding affinity for the radioisotope.
Possible chelator functionalities include acetates (monocarboxylic acids), acetylacetone, benzoylacetone, citric acid, 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, ethylenediamine-N,N,N',N'-tetraacetic acid, and pyridine-2,6-dicarboxylic acid.
The radioisotope is selected based on the type of emission, its half-life and the strength of its bond to the chelator, which must be sufficient so as not to be displaced by ions present in the blood. The preferred isotope is a beta emitter, because gamma radiation penetrates too deeply into tissue and the energy of alpha particles is insufficient. The half-life of the radioisotope should be between 24 hours and 2 months, preferably between 2-18 days. The shorter the half-life, the more problematic becomes the shipping and storage of the radioactive material, while the longer the half-life, the more excessive becomes the delivered the dosage in view of the biological process currently understood to be involved in the processes of restenosis.
CA 02206394 1997-0~-27 The most preferred combination of materials is a stainless steel stent, a gold base layer, alpha, omega mercaptoalkylamine as a spacer, Nl-(2-hydroxethyl)-ethylenedramine - N,N,Nl - triacetic acid as a chelator and Irl92 as the radioisotope.
In the practice of the invention, the stent first is prepared by applying the base layer, then optionally the spacer layer and finally the chelator. The coated stent subsequently is sterilized and processed along with the stent and associated devices. The subsequent shelf life and handling constraints substantially are dictated by the base stent and catheter rather than by the coating.
The radioisotope, suspended in a solution contained in a vial, is handled separately according to the general methods with which hospitals are acquainted. Just prior to implantation, the stent is immersed in the vial in order to allow the chelator to adsorb the radioisotope. The loaded stent subsequently is maneuvered into position within the patient and expanded to be permanently left in place. The radiation emitted by stent gradually diminishes as a function of its half-life but is sufficient during the critical six month time frame to preclude or at least minimize the chance of restenosis. Radiation subsequently continues to subside to insignificant levels obviating the need to remove the device.
While a particular form of the invention has been illustrated and described, it also will be apparent to those skilled in the art that various modifications can be made without departing from the scope of the invention. More particularly, any type of implantable device may be prepared in accordance with the invention and the method may b-e practiced to treat any type of condition that has been found to respond to the localized irradiation of tissue. Accordingly, it is not intended that the invention be limited except by the appended claims.
Claims (10)
1. An intravascular medical device for providing radiation treatment, comprising:
an implantable, component;
a chelating coating attached to a preselected surface of said component, said chelating coating being selected to have a binding affinity for a preselected radioisotope.
an implantable, component;
a chelating coating attached to a preselected surface of said component, said chelating coating being selected to have a binding affinity for a preselected radioisotope.
2. The medical device of claim 1, wherein said implantable component comprises an expandable stent.
3. The medical device of claim 1, further comprising a base layer attached to said preselected surface of said component and disposed below said chelating coating.
4. The medical device of claim 3, further comprising a spacer layer bonded to said base layer and disposed below said chelating coating.
5. The medical device of claim 4, wherein said base layer comprises gold and said spacer layer comprises alpha, omega mercapto-alkyamine.
6. The medical device of claim 1, further comprising a radioactive isotope adsorbed by said chelating coating.
7. The medical device of claim 6, wherein said radioactive isotope comprises a beta emitter.
8. The medical device of claim 7, wherein said beta emitter has a half-life of between 24 hours and 2 months.
9. The medical device of claim 8, wherein said beta emitter has a half-life of between 2 and 18 days.
10. A method for delivering a preselected dosage of radiation to a site within a patient, comprising the steps of:
providing an implantable component having preselected sections thereof coated with chelator said chelator being selected to have a bonding affinity for a preselected radioisotope;
providing said radioisotope in solution;
immersing said implantable component in said solution; and immediately after said immersion step, implanting said component in said patient.
providing an implantable component having preselected sections thereof coated with chelator said chelator being selected to have a bonding affinity for a preselected radioisotope;
providing said radioisotope in solution;
immersing said implantable component in said solution; and immediately after said immersion step, implanting said component in said patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/685,447 | 1996-07-19 | ||
US08/685,447 US5871436A (en) | 1996-07-19 | 1996-07-19 | Radiation therapy method and device |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2206394A1 true CA2206394A1 (en) | 1998-01-19 |
Family
ID=24752244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002206394A Abandoned CA2206394A1 (en) | 1996-07-19 | 1997-05-27 | Radiation therapy method and device |
Country Status (6)
Country | Link |
---|---|
US (2) | US5871436A (en) |
EP (1) | EP0819446A3 (en) |
JP (1) | JPH1057382A (en) |
AU (1) | AU696973B2 (en) |
CA (1) | CA2206394A1 (en) |
MX (1) | MX9705373A (en) |
Families Citing this family (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0633041T3 (en) | 1993-07-01 | 2000-04-03 | Schneider Europ Gmbh | Medical apparatus for the treatment of blood vessels by means of ionizing radiation |
US5857956A (en) | 1994-06-08 | 1999-01-12 | United States Surgical Corporation | Flexible source wire for localized internal irradiation of tissue |
EP0686342B1 (en) | 1994-06-10 | 1998-09-09 | Schneider (Europe) GmbH | A medical appliance for the treatment of a portion of body vessel by ionising radiation |
EP0965363B1 (en) | 1994-06-24 | 2002-02-13 | Schneider (Europe) GmbH | Medical appliance for the treatment of a portion of body vessel by ionizing radiation |
US6099454A (en) | 1996-02-29 | 2000-08-08 | Scimed Life Systems, Inc. | Perfusion balloon and radioactive wire delivery system |
US6234951B1 (en) | 1996-02-29 | 2001-05-22 | Scimed Life Systems, Inc. | Intravascular radiation delivery system |
US5855546A (en) | 1996-02-29 | 1999-01-05 | Sci-Med Life Systems | Perfusion balloon and radioactive wire delivery system |
US5782740A (en) * | 1996-08-29 | 1998-07-21 | Advanced Cardiovascular Systems, Inc. | Radiation dose delivery catheter with reinforcing mandrel |
US6261320B1 (en) | 1996-11-21 | 2001-07-17 | Radiance Medical Systems, Inc. | Radioactive vascular liner |
US5782742A (en) | 1997-01-31 | 1998-07-21 | Cardiovascular Dynamics, Inc. | Radiation delivery balloon |
US6287249B1 (en) | 1998-02-19 | 2001-09-11 | Radiance Medical Systems, Inc. | Thin film radiation source |
US6458069B1 (en) | 1998-02-19 | 2002-10-01 | Endology, Inc. | Multi layer radiation delivery balloon |
US6491619B1 (en) | 1997-01-31 | 2002-12-10 | Endologix, Inc | Radiation delivery catheters and dosimetry methods |
US6676590B1 (en) | 1997-03-06 | 2004-01-13 | Scimed Life Systems, Inc. | Catheter system having tubular radiation source |
US6110097A (en) | 1997-03-06 | 2000-08-29 | Scimed Life Systems, Inc. | Perfusion balloon catheter with radioactive source |
US6059713A (en) | 1997-03-06 | 2000-05-09 | Scimed Life Systems, Inc. | Catheter system having tubular radiation source with movable guide wire |
US6059812A (en) | 1997-03-21 | 2000-05-09 | Schneider (Usa) Inc. | Self-expanding medical device for centering radioactive treatment sources in body vessels |
AU7432298A (en) | 1997-04-26 | 1998-11-24 | Universitat Karlsruhe | Radionuclide microparticles bound to elastomeric hose for the endovascular therapy |
DE19718339A1 (en) | 1997-04-30 | 1998-11-12 | Schering Ag | Polymer coated stents, processes for their manufacture and their use for restenosis prophylaxis |
DE19724223C1 (en) * | 1997-04-30 | 1998-12-24 | Schering Ag | Production of radioactive coated stent, especially at point of use |
US6210312B1 (en) | 1997-05-20 | 2001-04-03 | Advanced Cardiovascular Systems, Inc. | Catheter and guide wire assembly for delivery of a radiation source |
US6019718A (en) | 1997-05-30 | 2000-02-01 | Scimed Life Systems, Inc. | Apparatus for intravascular radioactive treatment |
US6106454A (en) * | 1997-06-17 | 2000-08-22 | Medtronic, Inc. | Medical device for delivering localized radiation |
CH691846A5 (en) | 1997-06-20 | 2001-11-15 | Ecole Polytech | intravascular implant expansion deflector. |
US5919126A (en) * | 1997-07-07 | 1999-07-06 | Implant Sciences Corporation | Coronary stent with a radioactive, radiopaque coating |
EP1019145A1 (en) | 1997-09-23 | 2000-07-19 | United States Surgical Corporation | Source wire for radiation treatment |
EP0904798B1 (en) | 1997-09-26 | 2002-11-06 | Schneider ( Europe) GmbH | Carbon dioxide inflated radio-therapy balloon catheter |
US6254552B1 (en) * | 1997-10-03 | 2001-07-03 | E.I. Du Pont De Nemours And Company | Intra-coronary radiation devices containing Ce-144 or Ru-106 |
US6030333A (en) * | 1997-10-24 | 2000-02-29 | Radiomed Corporation | Implantable radiotherapy device |
US6264596B1 (en) * | 1997-11-03 | 2001-07-24 | Meadox Medicals, Inc. | In-situ radioactive medical device |
US6048299A (en) * | 1997-11-07 | 2000-04-11 | Radiance Medical Systems, Inc. | Radiation delivery catheter |
US6129658A (en) * | 1997-12-10 | 2000-10-10 | Varian Associates, Inc. | Method and apparatus creating a radioactive layer on a receiving substrate for in vivo implantation |
US6149574A (en) * | 1997-12-19 | 2000-11-21 | Radiance Medical Systems, Inc. | Dual catheter radiation delivery system |
US6120540A (en) * | 1998-01-21 | 2000-09-19 | Apple; Marc G. | Radio prosthesis |
US6224535B1 (en) | 1998-02-17 | 2001-05-01 | Advanced Cardiovascular Systems, Inc. | Radiation centering catheters |
DE19819426A1 (en) * | 1998-04-30 | 1999-11-11 | Christoph Hehrlein | Catheters and vascular supports, in particular for combined radioactive radiation and medication therapy and methods for their production |
DE19819635A1 (en) * | 1998-05-05 | 1999-11-11 | Jomed Implantate Gmbh | Radioactive stent |
US20060078493A1 (en) * | 1998-05-05 | 2006-04-13 | Randolf Von Oepen | Methods and apparatus for localized administration of inhibitory moieties to a patient |
US6053858A (en) * | 1998-06-04 | 2000-04-25 | Advanced Cardiovascular Systems, Inc. | Radiation source |
US6406488B1 (en) * | 1998-08-27 | 2002-06-18 | Heartstent Corporation | Healing transmyocardial implant |
US6413203B1 (en) | 1998-09-16 | 2002-07-02 | Scimed Life Systems, Inc. | Method and apparatus for positioning radioactive fluids within a body lumen |
US6224536B1 (en) * | 1999-02-08 | 2001-05-01 | Advanced Cardiovascular Systems | Method for delivering radiation therapy to an intravascular site in a body |
US6132677A (en) * | 1999-04-26 | 2000-10-17 | Lockheed Martin Energy Research Corporation | Method for making radioactive metal articles having small dimensions |
AU4924500A (en) * | 1999-05-19 | 2000-12-12 | Malte Neuss | Radially expandable vessel support |
US6547816B1 (en) | 1999-07-12 | 2003-04-15 | Civatech Corporation | Formable integral source material for medical devices |
FR2797175A1 (en) * | 1999-08-02 | 2001-02-09 | Jacques Seguin | Device for treatment of narrowing of vascular blood vessel or bilious duct, comprises catheter, radially extensible tubular element called stent, mounted on catheter, and means of expansion and radial deployment of stent |
EP1218570A1 (en) * | 1999-08-23 | 2002-07-03 | Angiogene, Inc. | Radioactively coated device and method of making same for preventing restenosis |
US6605031B1 (en) | 1999-09-22 | 2003-08-12 | Advanced Cardiovascular Systems, Inc. | Stepped centering balloon for optimal radiation delivery |
US6582417B1 (en) | 1999-09-22 | 2003-06-24 | Advanced Cardiovascular Systems, Inc. | Methods and apparatuses for radiation treatment |
US6352501B1 (en) | 1999-09-23 | 2002-03-05 | Scimed Life Systems, Inc. | Adjustable radiation source |
US6203485B1 (en) | 1999-10-07 | 2001-03-20 | Scimed Life Systems, Inc. | Low attenuation guide wire for intravascular radiation delivery |
US6398709B1 (en) | 1999-10-19 | 2002-06-04 | Scimed Life Systems, Inc. | Elongated member for intravascular delivery of radiation |
US6500108B1 (en) | 1999-10-22 | 2002-12-31 | The Regents Of The University Of California | Radiation delivery system and method |
ATE352268T1 (en) | 1999-11-23 | 2007-02-15 | Sorin Biomedica Cardio Srl | METHOD FOR TRANSFER OF RADIOACTIVE SUBSTANCES TO STENTS IN ANGIOPLASTY AND KIT |
US6491617B1 (en) * | 1999-12-30 | 2002-12-10 | St. Jude Medical, Inc. | Medical devices that resist restenosis |
US7163504B1 (en) | 2000-02-16 | 2007-01-16 | Advanced Cardiovascular Systems, Inc. | Multi-lumen fluted balloon radiation centering catheter |
US7994449B2 (en) | 2000-02-16 | 2011-08-09 | Advanced Cardiovascular Systems, Inc. | Square-wave laser bonding |
US6416457B1 (en) | 2000-03-09 | 2002-07-09 | Scimed Life Systems, Inc. | System and method for intravascular ionizing tandem radiation therapy |
US6302865B1 (en) | 2000-03-13 | 2001-10-16 | Scimed Life Systems, Inc. | Intravascular guidewire with perfusion lumen |
US6783793B1 (en) * | 2000-10-26 | 2004-08-31 | Advanced Cardiovascular Systems, Inc. | Selective coating of medical devices |
US6638205B1 (en) * | 2000-11-17 | 2003-10-28 | Mds (Canada) Inc. | Radioactive medical device for radiation therapy |
US6524232B1 (en) | 2000-12-22 | 2003-02-25 | Advanced Cardiovascular Systems, Inc. | Method for radioactive stent delivery |
US6641607B1 (en) | 2000-12-29 | 2003-11-04 | Advanced Cardiovascular Systems, Inc. | Double tube stent |
US6547812B1 (en) | 2000-12-29 | 2003-04-15 | Advanced Cardiovascular Systems, Inc. | Radiation therapy using a radioactive implantable device and a radiosensitizer agent |
US6800055B2 (en) | 2001-02-21 | 2004-10-05 | Cordis Corporation | Low attenuating radioactive seeds |
US6669621B2 (en) | 2001-03-14 | 2003-12-30 | Cordis Corporation | Method and assembly for containing radioactive materials |
US6497646B1 (en) | 2001-03-14 | 2002-12-24 | Cordis Corporation | Intravascular radiotherapy source ribbon having variable radiopacity |
US6764505B1 (en) | 2001-04-12 | 2004-07-20 | Advanced Cardiovascular Systems, Inc. | Variable surface area stent |
US20030153801A1 (en) * | 2001-05-29 | 2003-08-14 | Pharmacia Corporation | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease |
US7862495B2 (en) * | 2001-05-31 | 2011-01-04 | Advanced Cardiovascular Systems, Inc. | Radiation or drug delivery source with activity gradient to minimize edge effects |
US6656216B1 (en) * | 2001-06-29 | 2003-12-02 | Advanced Cardiovascular Systems, Inc. | Composite stent with regioselective material |
US8303651B1 (en) * | 2001-09-07 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Polymeric coating for reducing the rate of release of a therapeutic substance from a stent |
US7709048B2 (en) | 2002-05-02 | 2010-05-04 | Labcoat, Ltd. | Method and apparatus for coating a medical device |
US7048962B2 (en) * | 2002-05-02 | 2006-05-23 | Labcoat, Ltd. | Stent coating device |
US6645547B1 (en) * | 2002-05-02 | 2003-11-11 | Labcoat Ltd. | Stent coating device |
US8318235B2 (en) * | 2003-01-22 | 2012-11-27 | Cordis Corporation | Method for applying drug coating to a medical device in surgeon room |
WO2005011561A2 (en) | 2003-08-04 | 2005-02-10 | Labcoat, Ltd. | Stent coating apparatus and method |
US20050048194A1 (en) * | 2003-09-02 | 2005-03-03 | Labcoat Ltd. | Prosthesis coating decision support system |
US20050058768A1 (en) * | 2003-09-16 | 2005-03-17 | Eyal Teichman | Method for coating prosthetic stents |
US7198675B2 (en) | 2003-09-30 | 2007-04-03 | Advanced Cardiovascular Systems | Stent mandrel fixture and method for selectively coating surfaces of a stent |
CA2590515A1 (en) * | 2004-11-26 | 2006-06-01 | Stentomics Inc. | Chelating and binding chemicals to a medical implant, medical device formed, and therapeutic applications |
US7632307B2 (en) * | 2004-12-16 | 2009-12-15 | Advanced Cardiovascular Systems, Inc. | Abluminal, multilayer coating constructs for drug-delivery stents |
KR101406415B1 (en) | 2005-07-15 | 2014-06-19 | 미셀 테크놀로지즈, 인코포레이티드 | Polymer coatings containing drug powder of controlled morphology |
WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
US7867547B2 (en) | 2005-12-19 | 2011-01-11 | Advanced Cardiovascular Systems, Inc. | Selectively coating luminal surfaces of stents |
AU2007243268B2 (en) | 2006-04-26 | 2013-06-13 | Micell Technologies, Inc. | Coatings containing multiple drugs |
US8069814B2 (en) | 2006-05-04 | 2011-12-06 | Advanced Cardiovascular Systems, Inc. | Stent support devices |
US8603530B2 (en) | 2006-06-14 | 2013-12-10 | Abbott Cardiovascular Systems Inc. | Nanoshell therapy |
US8048448B2 (en) | 2006-06-15 | 2011-11-01 | Abbott Cardiovascular Systems Inc. | Nanoshells for drug delivery |
US8017237B2 (en) | 2006-06-23 | 2011-09-13 | Abbott Cardiovascular Systems, Inc. | Nanoshells on polymers |
US7686756B2 (en) * | 2006-08-29 | 2010-03-30 | Ciratech Oncology | Brachytherapy devices and related methods and computer program products |
US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
JP5603598B2 (en) | 2007-01-08 | 2014-10-08 | ミセル テクノロジーズ、インコーポレイテッド | Stent with biodegradable layer |
US8048441B2 (en) | 2007-06-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Nanobead releasing medical devices |
BRPI0910969B8 (en) | 2008-04-17 | 2021-06-22 | Micell Technologies Inc | device |
JP2011528275A (en) | 2008-07-17 | 2011-11-17 | ミセル テクノロジーズ,インク. | Drug delivery medical device |
JP2012522589A (en) | 2009-04-01 | 2012-09-27 | ミシェル テクノロジーズ,インコーポレイテッド | Covered stent |
EP3366326A1 (en) | 2009-04-17 | 2018-08-29 | Micell Technologies, Inc. | Stents having controlled elution |
EP2453834A4 (en) | 2009-07-16 | 2014-04-16 | Micell Technologies Inc | Drug delivery medical device |
EP2531140B1 (en) | 2010-02-02 | 2017-11-01 | Micell Technologies, Inc. | Stent and stent delivery system with improved deliverability |
EP2560576B1 (en) | 2010-04-22 | 2018-07-18 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
WO2012009684A2 (en) | 2010-07-16 | 2012-01-19 | Micell Technologies, Inc. | Drug delivery medical device |
WO2013012689A1 (en) | 2011-07-15 | 2013-01-24 | Micell Technologies, Inc. | Drug delivery medical device |
US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
EP2967803B1 (en) | 2013-03-12 | 2023-12-27 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
KR102079613B1 (en) | 2013-05-15 | 2020-02-20 | 미셀 테크놀로지즈, 인코포레이티드 | Bioabsorbable biomedical implants |
CN108136203A (en) * | 2015-08-17 | 2018-06-08 | 波士顿科学国际有限公司 | Radiant stand |
GB2546319B (en) * | 2016-01-15 | 2019-07-03 | Cook Medical Technologies Llc | Coated medical device and method of coating such a device |
US11752019B2 (en) | 2018-11-29 | 2023-09-12 | Cook Medical Technologies Llc | Bioactive agent coated medical device and method of coating such a device |
EP3659634B1 (en) | 2018-11-29 | 2023-02-22 | Cook Medical Technologies LLC | Bioactive agent coated medical device and method of coating such a device |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0165993A1 (en) * | 1983-12-27 | 1986-01-02 | The Board Of Trustees Of The Leland Stanford Junior University | Catheter for treatment of tumors and method for using same |
US4697575A (en) * | 1984-11-21 | 1987-10-06 | Henry Ford Hospital | Delivery system for interstitial radiation therapy including substantially non-deflecting elongated member |
US4706652A (en) * | 1985-12-30 | 1987-11-17 | Henry Ford Hospital | Temporary radiation therapy |
US4994560A (en) * | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
US5575815A (en) * | 1988-08-24 | 1996-11-19 | Endoluminal Therapeutics, Inc. | Local polymeric gel therapy |
US4861520A (en) * | 1988-10-28 | 1989-08-29 | Eric van't Hooft | Capsule for radioactive source |
US4969863A (en) * | 1988-10-28 | 1990-11-13 | Eric van't Hooft | Adaptor for remote after-loading apparatus for radiotherapy |
US5180368A (en) * | 1989-09-08 | 1993-01-19 | Advanced Cardiovascular Systems, Inc. | Rapidly exchangeable and expandable cage catheter for repairing damaged blood vessels |
US5002560A (en) * | 1989-09-08 | 1991-03-26 | Advanced Cardiovascular Systems, Inc. | Expandable cage catheter with a rotatable guide |
US5034001A (en) * | 1989-09-08 | 1991-07-23 | Advanced Cardiovascular Systems, Inc. | Method of repairing a damaged blood vessel with an expandable cage catheter |
US5263963A (en) * | 1989-09-08 | 1993-11-23 | Advanced Cardiovascular Systems, Inc. | Expandable cage catheter for repairing a damaged blood vessel |
US5320824A (en) * | 1989-10-12 | 1994-06-14 | Mallinckrodt Medical, Inc. | Radionuclide labelled particles useful for radiation synovectomy |
US5059166A (en) * | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5176617A (en) * | 1989-12-11 | 1993-01-05 | Medical Innovative Technologies R & D Limited Partnership | Use of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct |
US5199939B1 (en) * | 1990-02-23 | 1998-08-18 | Michael D Dake | Radioactive catheter |
US5213561A (en) * | 1990-09-06 | 1993-05-25 | Weinstein Joseph S | Method and devices for preventing restenosis after angioplasty |
US5354257A (en) * | 1991-01-29 | 1994-10-11 | Med Institute, Inc. | Minimally invasive medical device for providing a radiation treatment |
US5484384A (en) * | 1991-01-29 | 1996-01-16 | Med Institute, Inc. | Minimally invasive medical device for providing a radiation treatment |
US5137709A (en) * | 1991-02-15 | 1992-08-11 | The Dow Chemical Company | Layered mixed metal hydroxides for the stabilization of radioactive colloids |
US5133956A (en) * | 1991-05-30 | 1992-07-28 | The Dow Chemical Company | Radiolabeled metal-binding protein for the treatment of arthritis |
AU2597292A (en) * | 1991-09-05 | 1993-04-05 | Cedars-Sinai Medical Center | Method and apparatus for restenosis treatment |
US5302168A (en) * | 1991-09-05 | 1994-04-12 | Hess Robert L | Method and apparatus for restenosis treatment |
JP3682974B2 (en) * | 1991-11-27 | 2005-08-17 | 株式会社ファノスディベロップメント | Compounds, compositions, and methods for binding bioactive substances to bioparticle surface membranes |
GB9203037D0 (en) * | 1992-02-11 | 1992-03-25 | Salutar Inc | Contrast agents |
JPH09501326A (en) * | 1993-05-04 | 1997-02-10 | オムニトロン インターナショナル インコーポレイテッド | Radiation source wire, device using the same, and treatment method |
US5456667A (en) * | 1993-05-20 | 1995-10-10 | Advanced Cardiovascular Systems, Inc. | Temporary stenting catheter with one-piece expandable segment |
DK0633041T3 (en) * | 1993-07-01 | 2000-04-03 | Schneider Europ Gmbh | Medical apparatus for the treatment of blood vessels by means of ionizing radiation |
US5498227A (en) * | 1993-09-15 | 1996-03-12 | Mawad; Michel E. | Retrievable, shielded radiotherapy implant |
JP2703510B2 (en) | 1993-12-28 | 1998-01-26 | アドヴァンスド カーディオヴァスキュラー システムズ インコーポレーテッド | Expandable stent and method of manufacturing the same |
US5503613A (en) * | 1994-01-21 | 1996-04-02 | The Trustees Of Columbia University In The City Of New York | Apparatus and method to reduce restenosis after arterial intervention |
US5618266A (en) * | 1994-03-31 | 1997-04-08 | Liprie; Samuel F. | Catheter for maneuvering radioactive source wire to site of treatment |
US5503614A (en) * | 1994-06-08 | 1996-04-02 | Liprie; Samuel F. | Flexible source wire for radiation treatment of diseases |
EP0965363B1 (en) * | 1994-06-24 | 2002-02-13 | Schneider (Europe) GmbH | Medical appliance for the treatment of a portion of body vessel by ionizing radiation |
US5730698A (en) * | 1995-05-09 | 1998-03-24 | Fischell; Robert E. | Balloon expandable temporary radioisotope stent system |
US5609629A (en) * | 1995-06-07 | 1997-03-11 | Med Institute, Inc. | Coated implantable medical device |
CA2248076A1 (en) * | 1996-03-11 | 1997-09-18 | Richard D. Leavitt | Polymeric delivery of radionuclides and radiopharmaceuticals |
EP0894012A2 (en) * | 1996-04-17 | 1999-02-03 | Olivier Bertrand | Radioactivity local delivery system |
US5924973A (en) * | 1996-09-26 | 1999-07-20 | The Trustees Of Columbia University In The City Of New York | Method of treating a disease process in a luminal structure |
DE19724223C1 (en) * | 1997-04-30 | 1998-12-24 | Schering Ag | Production of radioactive coated stent, especially at point of use |
AU8399998A (en) * | 1997-07-11 | 1999-02-08 | Innerdyne, Inc. | Methods and systems for preparing and sealing radiation delivery structures |
-
1996
- 1996-07-19 US US08/685,447 patent/US5871436A/en not_active Expired - Lifetime
-
1997
- 1997-05-21 AU AU23541/97A patent/AU696973B2/en not_active Ceased
- 1997-05-27 CA CA002206394A patent/CA2206394A1/en not_active Abandoned
- 1997-07-04 EP EP97304916A patent/EP0819446A3/en not_active Withdrawn
- 1997-07-16 MX MX9705373A patent/MX9705373A/en unknown
- 1997-07-22 JP JP19590897A patent/JPH1057382A/en not_active Withdrawn
-
1999
- 1999-02-10 US US09/247,632 patent/US6210313B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AU696973B2 (en) | 1998-09-24 |
JPH1057382A (en) | 1998-03-03 |
EP0819446A3 (en) | 2000-01-26 |
MX9705373A (en) | 1998-04-30 |
US6210313B1 (en) | 2001-04-03 |
AU2354197A (en) | 1998-01-29 |
US5871436A (en) | 1999-02-16 |
EP0819446A2 (en) | 1998-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5871436A (en) | Radiation therapy method and device | |
MXPA97005373A (en) | Method and device for radiac therapy | |
US7018371B2 (en) | Combination ionizing radiation and radiosensitizer delivery devices and methods for inhibiting hyperplasia | |
KR100228188B1 (en) | A radioactive stent and process for preparation thereof | |
US6106454A (en) | Medical device for delivering localized radiation | |
US6390967B1 (en) | Radiation for inhibiting hyperplasia after intravascular intervention | |
US6537195B2 (en) | Combination x-ray radiation and drug delivery devices and methods for inhibiting hyperplasia | |
US5840008A (en) | Radiation emitting sleeve catheter and methods | |
DE69729778T2 (en) | Stent for the dilation of stenotic damage of a blood vessel | |
US6685618B2 (en) | Method for delivering radiation to an intraluminal site in the body | |
US5873811A (en) | Composition containing a radioactive component for treatment of vessel wall | |
US5851171A (en) | Catheter assembly for centering a radiation source within a body lumen | |
US6224536B1 (en) | Method for delivering radiation therapy to an intravascular site in a body | |
JP3372950B2 (en) | Drug delivery system | |
US6458069B1 (en) | Multi layer radiation delivery balloon | |
US20060015170A1 (en) | Contrast coated stent and method of fabrication | |
US20020010383A1 (en) | Apparatus and method to treat a disease process in a luminal structure | |
US20050147644A1 (en) | Reduced restenosis drug containing stents | |
WO2001024734A1 (en) | A chamber for applying therapeutic substances to an implantable device | |
JP2010264275A (en) | Coated medical device | |
JP2001509493A (en) | Methods and systems for preparation and sealing of radiation delivery structures | |
NZ314866A (en) | Intravascular implantable stent with a chelating coating that binds to a preselected radioisotope | |
WO1999040962A1 (en) | Radiation centering catheter with blood perfusion capability | |
Tamai et al. | 15. THE IGAKI-TAMAI® STENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |